Companies / Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc
Nasdaq: KNSACIK 1730430LONDON
Financials · FY2025
Ownership
156.0M shares outstanding · as of Jul 24, 2026
Ownership
Share classes
| Common Stock | 50.00% | |
| Class A | 30.95% | |
| Class B | 10.29% | |
| Class A | 8.19% | |
| Class B | 0.57% |
| 10%+ / strategic | 3.11% | 4,854,354 |
| Institutions | 28.45% | 44,394,314 |
| Public float | 68.44% | 106,799,358 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 12
View all →| Insider | % of shares | Shares |
|---|---|---|
667, L.P.Director | — | — |
Baker Bros. Advisors (GP) LLCDirector | — | — |
Baker Bros. Advisors LPDirector | — | — |
Baker Brothers Life Sciences LPDirector | — | — |
Baker FelixDirector | — | — |
Baker JulianDirector | — | — |
Cole G BradleyDirector | — | — |
Levy Richard SDirector | — | — |
Paolini John F.CHIEF MEDICAL OFFICER | — | — |
Popovits Kimberly JDirector | — | — |
Institutional holders 232
View all →| Holder | Value | % of shares |
|---|---|---|
| $175.20M | 1.76% | |
| $137.31M | 2.13% | |
| $136.08M | 1.81% | |
| $128.41M | 1.99% | |
| $108.81M | 1.45% | |
| $67.77M | 1.05% | |
| $56.10M | 0.87% | |
| $54.44M | 0.85% | |
| $46.19M | 0.61% | |
| $45.03M | 0.45% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common stock | $146.64M | +2.3M +513.43% | 2,739,615 1.76% of shares | high |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common stock | $40.36M | +631K +864.62% | 704,194 0.45% of shares | medium |
| Q1 2026 as of | Balyasny Asset Management L.P. 13F manager | New | Common stock | $24.06M | +500K | 499,792 0.32% of shares | medium |
| Q1 2026 as of | Janus Henderson Group PLC 13F manager | Add | Common stock | $15.80M | +328K +213.52% | 481,023 0.31% of shares | medium |
| Q2 2026 as of | Deutsche Bank AG 13F manager | Trim | Common stock | $-15.52M | -243K -38.50% | 387,606 0.25% of shares | medium |
| Q1 2026 as of | Penn Capital Management Company, LLC 13F manager | New | Common stock | $14.56M | +302K | 301,993 0.19% of shares | medium |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Add | Common stock | $14.42M | +300K +5165.02% | 305,371 0.20% of shares | medium |
| Q1 2026 as of | D. E. Shaw & Co., Inc. 13F manager | Trim | Common stock | $-13.60M | -282K -22.74% | 959,257 0.61% of shares | medium |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vanguard Group Inc | Passive13G/A | — |
| Rubric Capital Management LP | Passive13G/A | — |
| Fmr LLC | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| KNSA | — | G52694109 |